Evaluation of the performance of a novel HIV ‐1 viral load assay for HIV quantification in China
HIV Medicine · 2023
DOI: 10.1111/hiv.13473 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2023. Verfasst von Xizi Deng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, HIV Seropositivity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Guangzhou Science and Technology Plan Project: 202201011646.
Abstract (Originalsprache)
Objectives
Our objective was to assess the HIV‐1 quantification performance of the Livzon HIV‐1 viral load (VL) assay and the Roche Cobas HIV‐1 assay to evaluate an HIV‐1 VL testing reagent for application in China.
Method
We compared the Livzon and Roche Cobas HIV‐1 VL assays using ethylenediaminetetraacetic acid plasma samples collected between May 2021 and November 2021 from patients with HIV‐1 and healthy controls. We used Cohen's κ coefficient to measure agreement of qualitative values and Pearson's correlation coefficient ( r ) values and the coefficient of determination ( R 2 ) to determine the linear relationship between the two assays. We performed a Bland–Altman analysis to assess VL quantification agreement.
Results
In total, 11 plasma samples from patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) and nine samples from healthy controls were undetectable on both assays. Overall agreement was seen in 419 of 500 specimens (91.40%), with a κ value of 0.59. Pearson's correlation coefficient between the two assays was 0.970. Using the Bland–Altman method, 95.14% (352/370) of paired VLs fell within the 95% confidence limits of agreement (−0.51 to 0.95 log 10 copies/mL). Higher VLs had a better correlation and a smaller mean difference between the two assays. Pearson's correlation coefficient for the samples of subtype CRF01_AE, CRF07_BC, and CRF55_01B was 0.950, 0.935, and 0.952, respectively.
Conclusion
The Livzon HIV‐1 VL assay exhibits good precision and linearity and a high correlation with the Roche Cobas HIV‐1 assay. The Livzon HIV‐1 VL assay has salient advantages in terms of the lyophilized powder reagent, which gives the assay greater stability and sensitivity and can be readily used in low‐resource areas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Förderung
- Guangzhou Science and Technology Plan Project: 202201011646
Zitieren
APA
Deng, X., Li, L., Cai, X., Lin, Y., & Lan, Y. (2023). Evaluation of the performance of a novel HIV ‐1 viral load assay for HIV quantification in China. HIV Medicine. https://doi.org/10.1111/hiv.13473
Vancouver
Deng X, Li L, Cai X, Lin Y, Lan Y. Evaluation of the performance of a novel HIV ‐1 viral load assay for HIV quantification in China. HIV Medicine. 2023. doi:10.1111/hiv.13473
BibTeX
@article{Deng2023,
author = {Deng, Xizi and Li, Liya and Cai, Xiaoli and Lin, Yaqing and Lan, Yun},
title = {Evaluation of the performance of a novel HIV ‐1 viral load assay for HIV quantification in China},
journal = {HIV Medicine},
year = {2023},
doi = {10.1111/hiv.13473}
}
EUVIMED